Verastem (VSTM) Cash from Investing Activities (2011 - 2026)
Verastem's (VSTM) quarterly Cash from Investing Activities came in at -$16.0 million in Q1 2026, down 1090.71% quarter-over-quarter from -$1.3 million in Q4 2025.
Verastem (VSTM) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Verastem's Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$16.0 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$16.0 million in Q1 2026; TTM through Mar 2026 was -$17.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$9.6 million, down 116.05% from the prior year.
- Cash from Investing Activities fell to -$16.0 million in Q1 2026 per VSTM's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $31.0 million in Q1 2024 and bottomed at -$70.1 million in Q3 2023.
- The 5-year median for Cash from Investing Activities is $12.7 million (2022), against an average of $5.4 million.
- Across the five-year window, Cash from Investing Activities surged 19634.85% in 2022 and slumped 1608.05% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at $13.0 million in 2022, then slipped by 4.52% to $12.4 million in 2023, then soared by 133.14% to $29.0 million in 2024, then tumbled by 104.64% to -$1.3 million in 2025, then tumbled by 1090.71% to -$16.0 million in 2026.
- Per Business Quant, the three latest VSTM Cash from Investing Activities figures stand at -$16.0 million (Q1 2026), -$1.3 million (Q4 2025), and $29.0 million (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Verastem | 614.82 Mn | 416.99 Mn | 15.90 Mn | -16.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.02 Mn |
| Mar 31, 2026 | -16.02 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Jun 30, 2024 | 28.99 Mn |
| Jun 30, 2024 | 28.99 Mn |
| Mar 31, 2024 | 30.98 Mn |
| Mar 31, 2024 | 30.98 Mn |
| Dec 31, 2023 | 12.44 Mn |
| Dec 31, 2023 | 12.44 Mn |
| Sep 30, 2023 | -70.08 Mn |
| Sep 30, 2023 | -70.08 Mn |
| Jun 30, 2023 | 14.00 Mn |
| Jun 30, 2023 | 14.00 Mn |
| Mar 31, 2023 | -804,000.00 |
| Mar 31, 2023 | -804,000.00 |
| Dec 31, 2022 | 13.03 Mn |
| Dec 31, 2022 | 13.03 Mn |
| Sep 30, 2022 | 4.65 Mn |
| Sep 30, 2022 | 4.65 Mn |